Dutasteride was patented in 1996  and was first described in the scientific literature in 1997.  It was approved by the FDA for the treatment of BPH in November 2001 and was introduced into the . market the following year under the brand name Avodart.  Dutasteride has subsequently been introduced in many other countries as well, including throughout Europe and South America .  The patent protection of dutasteride expired in November 2015 and the drug has since become available in the . in a variety of low-cost generic formulations . 
Q. I have met my close friend after 3 years. She is showing some signs of high depression. How can I help her? I have met my very close friend after 3 years and she is very depressed. I am worried that she is showing some signs of high depression. She talks all rubbish and negatives these days which is filled with that nonsense hopelessness. She was fine and going good when I left her and now she is completely negative in her behavior and also very depressed. She is not able to enjoy my company. She had lost her weight and her eyes reflect the bluntness. She keeps silent most of the time. How can I help her? A. I think first you must talk to her and find out about when and how this started. Take her to all the places where you both used to go. She might have come across difficult phase in these years which would have made her depressed and she may need a support to bring her back to normal way of living. We cannot say that this is a depression which would get cured by just talking and knowing the reasons but you must help her to fight back for the thing she had lost. If there is no desired result, then do consult a physician.
Anticoagulants: Patients on anticoagulants such as warfarin should be carefully monitored during anabolic steroid therapy as anabolic steroids may increase sensitivity to oral anticoagulants which may require a concomitant reduction in anticoagulant dosage to achieve a desirable prothrombin time (PT). Anticoagulant patients should be monitored regularly during anabolic steroid therapy, particularly during initiation and termination of therapy. Warfarin patients should have INR and PT monitored throughout androgen therapy and warfarin dosages titrated to achieve the desired INR and PT. Such patients should be monitored for occult bleeding.